Fungal CNS infections in patients with hematologic malignancy

References

• Denning DW. Invasive aspergillosis. Clin. Infect. Dis. 26, 781–805 (1998).
   PubMed Web of Science ®Google Scholar
• Manuel RJ, Kibbler CC. The epidemiology and prevention of invasive aspergillosis. J. Hosp. Infect. 39, 95–106 (1998).
   PubMed Web of Science ®Google Scholar
• Patterson TF, Kirkpatrick WR, White M et al. for the I3 Aspergillus Study Group. Invasive aspergillosis. Disease spectrum, treatment, practices and outcomes. Medicine 79, 250–260 (2000).
   PubMed Web of Science ®Google Scholar
• Pagano L, Girmenia C, Mele L et al. for GIMEMA Infection Program. Infections caused by filamentous fungi in patients with hematological malignancies. A report of 391 cases by GIMEMA infection. Haematologica 86, 862–870 (2001).
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100, 4358–4366 (2002).
   PubMed Web of Science ®Google Scholar
• Subirà M, Martino R, Franquet T et al. Invasive pulmonary aspergillosis in patients with hematologic malignancies: survival and prognostic factors. Haematologica 87, 528–534 (2002).
   PubMed Web of Science ®Google Scholar
• Gerson SL, Talbot GH, Hurwitz S et al. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann. Intern. Med. 100(3), 345–351 (1984).
   PubMed Web of Science ®Google Scholar
• Ng TT, Robson GD, Denning DW. Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology 140(Pt 9), 2475–2479 (1994).
   PubMed Web of Science ®Google Scholar
• Dubey A, Patwardhan RV, Sampth S, Santosh V, Kolluri S, Nanda A. Intracranial fungal granuloma: analysis of 40 patients and review of the literature. Surg. Neurol. 63(3), 254–260 (2005).
   PubMedGoogle Scholar
• Kume H, Yamazaki T, Abe M, Tanuma H, Okudaira M, Okayasu I. Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS: comparison of the data from the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993 and 1997. Pathol. Int. 53, 744–750 (2003).
   PubMed Web of Science ®Google Scholar
• Kami M, Machida U, Okuzumi K et al. Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy. Br. J. Haematol. 117, 40–46 (2002).
   PubMed Web of Science ®Google Scholar
• Hori A, Kami M, Kishi Y, Machida U, Matsumura T, Kashima T. Clinical significance of extra-pulmonary involvement of invasive aspergillosis: a retrospective autopsy-based study of 107 patients. J. Hosp. Infect. 50(3), 175–182 (2002).
   PubMed Web of Science ®Google Scholar
• Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. 32, 358–366 (2001).
   PubMed Web of Science ®Google Scholar
• Baddley JW, Salzman D, Pappas PG. Fungal brain abscess in transplant recipients: epidemiologic, microbiologic, and clinical features. Clin. Transplant. 16(6), 419–424 (2002).
   PubMed Web of Science ®Google Scholar
• Ashdown BC, Tien RD, Felsberg GJ. Aspergillosis of the brain and paranasal sinuses in immunocompromised patients: CT and MR imaging findings. Am. J. Roentgenol. 162(1), 155–159 (1994).
   PubMed Web of Science ®Google Scholar
• Yamada K, Shrier DA, Rubio A et al. Imaging findings in intracranial aspergillosis. Acad. Radiol. 9(2), 163–171 (2002).
   PubMed Web of Science ®Google Scholar
• Wilson BG. CT assessment of CNS complications of AIDS. Radiol. Technol. 73(5), 424–437 (2002).
   PubMedGoogle Scholar
• Innocenti R, Degl’Innocenti L, Fronzaroli C, Ferrante F, Corradi F. Radiologic miliary patterns of cerebral tuberculosis. Arch. Neurol. 62(1), 153–154 (2005).
   PubMedGoogle Scholar
• Carradice D, Szer J. Cerebral nocardiosis after allogeneic bone marrow transplantation. Intern. Med. J. 34(12), 698–699 (2004).
   PubMed Web of Science ®Google Scholar
• Kami M, Shirouzu I, Mitani K et al. Early diagnosis of central nervous system aspergillosis with combination use of cerebral diffusion-weighted echo-planar magnetic resonance image and polymerase chain reaction of cerebrospinal fluid. Intern. Med. 38(1), 45–48 (1999).
   PubMed Web of Science ®Google Scholar
• Viscoli C, Machetti M, Gazzola P et al. Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J. Clin. Microbiol. 40(4), 1496–1499 (2002).
   PubMed Web of Science ®Google Scholar
• Groll AH, Giri N, Petraitis V et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J. Infect. Dis. 182(1), 274–282 (2000).
   PubMed Web of Science ®Google Scholar
• Barrett JP, Vardulaki KA, Conlon C et al. Amphotericin B Systematic Review Study Group. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin. Ther. 25(5), 1295–1320 (2003).
   PubMed Web of Science ®Google Scholar
• Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HB. Voriconazole. Clin. Ther. 25(5), 1321–1381 (2003).
   PubMed Web of Science ®Google Scholar
• Vermes A, van Der Sijjs H, Guchelaar HJ. Flucytosine: correlation between toxicity and pharmacokinetic parameters. Chemotherapy 46, 86–94 (2000).
   PubMed Web of Science ®Google Scholar
• Naim-Url-Rahman, Troke PF, Schwartz S et al. Voriconazole therapy in 86 patients with CNS aspergillosis: a retrospective analysis. Interscience Conference on Antimicrobial Agents and Chemotherapy (2003).
   Google Scholar
• Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev. Infect. Dis. 12(6), 1147–1201 (1990).
   PubMedGoogle Scholar
• Siddiqui AA, Shah AA, Bashir SH. Craniocerebral aspergillosis of sinonasal origin in immunocompetent patients: clinical spectrum and outcome in 25 cases. Neurosurgery 55(3), 602–611 (2004).
   PubMed Web of Science ®Google Scholar
• Pagano L, Ricci P, Tonso A et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto) Br. J. Haematol. 99(2), 331–336 (1997).
   PubMed Web of Science ®Google Scholar
• Jantunen E, Volin L, Salonen O et al. Central nervous system aspergillosis in allogeneic stem cell transplant recipients. Bone Marrow Transplant. 31(3), 191–196 (2003).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Lutsar I, Driscoll T et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr. Infect. Dis. J. 21, 240–248 (2002).
   PubMed Web of Science ®Google Scholar
• Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. 34(5), 563–571 (2002).
   PubMed Web of Science ®Google Scholar
• Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36(9), 1122–1131 (2003).
   PubMed Web of Science ®Google Scholar
• Troke PF, Schwartz S, Ruhnke M et al. Voriconazole therapy in 86 patients with CNS aspergillosis: a retrospective analysis. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (2003).
   Google Scholar
• Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin. Infect. Dis. 37, S188–S224 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob. Agents Chemother. 48(3), 693–715 (2004).
   PubMed Web of Science ®Google Scholar
• Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. 39(6), 797–802 (2004).
   PubMed Web of Science ®Google Scholar
• Damaj G, Ivanov V, Le Brigand B et al. Rapid improvement of disseminated aspergillosis with caspofungin/voriconazole combination in an adult leukemic patient. Ann. Hematol. 83(6), 390–393 (2004).
   PubMed Web of Science ®Google Scholar
• Tattevin P, Bruneel F, Lellouche F et al. Successful treatment of brain aspergillosis with voriconazole. Clin. Microbiol. Infect. 10(10), 928–931 (2004).
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Hachem R, Lewis RE et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98, 292–299 (2003).
   PubMed Web of Science ®Google Scholar
• Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob. Agents Chemother. 45(1), 327–330 (2001).
   PubMed Web of Science ®Google Scholar
• Bartizal K, Gill CJ, Abruzzo GK et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41(11), 2326–2332 (1997).
   PubMed Web of Science ®Google Scholar
• Franzot SP, Casadevall A. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob. Agents Chemother. 41(2), 331–336 (1997).
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev. Iberoam. Micol. 20(4), 121–136 (2003).
   PubMedGoogle Scholar
• Chandrasekar PH, Cutright JL, Manavathu EK. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis. Clin. Microbiol. Infect. 10(10), 925–928 (2004).
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34, 909–917 (2002).
   PubMed Web of Science ®Google Scholar
• Pagano L, Offidani M, Fianchi L et al. Mucormycosis in hematological patients. Haematologica 89, 207–214 (2004).
   PubMed Web of Science ®Google Scholar
• Gleissner B, Schilling A, Anagnostopolous I, Siehl I, Thiel E. Improved outcome of zygomycosis in patients with hematological diseases? Leuk. Lymphoma 45(7), 1351–1360 (2004).
   PubMed Web of Science ®Google Scholar
• Dannaoui E, Meis JF, Loebenberg D, Verweij PE. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob. Agents Chemother. 47(11), 3647–3650 (2003).
   PubMed Web of Science ®Google Scholar
• Herbrecht R. Posaconazole: a potent, extended-spectrum triazole antifungal for the treatment of serious fungal infections. Int. J. Clin. Pract. 58(6), 612–624 (2004).
   PubMed Web of Science ®Google Scholar
• Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob. Agents Chemother. 46(5), 1581–1582 (2002).
   PubMed Web of Science ®Google Scholar
• Handzel O, Landau Z, Halperin D. Liposomal amphotericin B treatment for rhinocerebral mucormycosis: how much is enough? Rhinology 41(3), 184–186 (2003).
   PubMed Web of Science ®Google Scholar
• Barron MA, Lay M, Madinger NE. Surgery and treatment with high-dose liposomal amphotericin B for eradication of craniofacial zygomycosis in a patient with Hodgkin’s disease who had undergone allogeneic hematopoietic stem cell transplantation. J. Clin. Microbiol. 43(4), 2012–2014 (2005)
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother. 46, 1032–1037 (2002).
   PubMed Web of Science ®Google Scholar
• Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J. Antimicrob. Chemother. 51, 45–52 (2003).
   PubMed Web of Science ®Google Scholar
• Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N. Engl. J. Med. 350, 950–952 (2004).
   PubMed Web of Science ®Google Scholar
• Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin. Infect. Dis. 39, 743–746 (2004).
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Lionakis MS, Lewis RE et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J. Infect. Dis. 191, 350–360 (2005).
   Google Scholar
• Greenberg RN, Anstead G, Herbrecht R et al. Posaconazole (POS) experience in the treatment of zygomycosis. 42 Interscience Conference on Antimicrobial Agents and Chemotherapy. CA, USA, September 14–17 (2003).
   Google Scholar
• Guo LS. Amphotericin B colloidal dispersion: an improved antifungal therapy. Adv. Drug Deliv. Rev. 47(2–3), 149–163 (2001).
   PubMed Web of Science ®Google Scholar
• Larkin JA, Montero JA. Efficacy and safety of amphotericin B lipid complex for zygomycosis. Infect. Med. 20, 201–206 (2003).
   Web of Science ®Google Scholar
• Walsh TH, Goodman JL, Pappas P et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (Ambisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob. Agents Chemother. 45, 3487–3496 (2001).
   PubMed Web of Science ®Google Scholar
• Nesky MA, McDougal EC, Peacock JE Jr. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Clin. Infect. Dis. 31(3), 673–677 (2000).
   PubMed Web of Science ®Google Scholar
• Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob. Agents Chemother. 45, 2151–2153 (2001).
   PubMed Web of Science ®Google Scholar
• Uchida K, Yokota N, Yamaguchi H. In vitro antifungal activity of posaconazole against various pathogenic fungi. Int. J. Antimicrob. Agents 18, 167–172 (2001).
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Winston DJ, Mukwaya G, Schiller GJ. Treatment of Scedosporium apiospermum brain abscesses with posaconazole.Clin. Infect. Dis. 1534(12), 1648–1650 (2002)
   Google Scholar
• Revankar SG, Sutton DA, Rinaldi MG. Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin. Infect. Dis. 38(2), 206–216 (2004).
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie EJ, Queiroz-Telles F et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 98(2), 315–319 (2003).
   PubMed Web of Science ®Google Scholar
• Agamanolis DP, Kalwinsky DK, Krill CE Jr, Dasu S, Halasa B, Galloway PG. Fusarium meningoencephalitis in a child with acute leukemia. Neuropediatrics 22(2), 110–112 (1991).
   PubMed Web of Science ®Google Scholar
• Voice RA, Bradley SF, Sangeorzan JA, Kauffman CA. Chronic candidal meningitis: an uncommon manifestation of candidiasis. Clin. Infect. Dis. 19(1), 60–66 (1994).
   PubMed Web of Science ®Google Scholar
• Viscoli C, Girmenia C, Marinus A et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin. Infect. Dis. 28, 1071–1079 (1999).
   PubMed Web of Science ®Google Scholar
• Lai PH, Lin SM, Pan HB, Yang CF. Disseminated miliary cerebral candidiasis. Am. J. Neuroradiol. 18(7), 1303–1306 (1997).
   PubMed Web of Science ®Google Scholar
• Chen TL, Tsai CA, Fung CP, Lin MY, Yu KW, Liu CY. Clinical significance of Candida species isolated from cerebrospinal fluid. J. Microbiol. Immunol. Infect. 35(4), 249–254 (2002).
   PubMedGoogle Scholar
• Sanchez-Portocarrero J, Perez-Cecilia E, Corral O, Romero-Vivas J, Picazo JJ. The central nervous system and infection by Candida species. Diagn. Microbiol. Infect. Dis. 37(3), 169–179 (2000).
   PubMed Web of Science ®Google Scholar
• Verduyn Lunel FM, Voss A, Kuijper EJ et al. Detection of the Candida antigen mannan in cerebrospinal fluid specimens from patients suspected of having Candida meningitis. J. Clin. Microbiol. 42(2), 867–870 (2004).
   PubMed Web of Science ®Google Scholar
• Ralph ED, Hussain Z. Chronic meningitis caused by Candida albicans in a liver transplant recipient: usefulness of the polymerase chain reaction for diagnosis and for monitoring treatment. Clin. Infect. Dis. 23(1), 191–192 (1996).
   PubMedGoogle Scholar
• Pappas PG, Rex JH, Sobel JD et al. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38(2), 161–189 (2004).
   PubMed Web of Science ®Google Scholar
• Stevens DA, Shatsky SA. Intrathecal amphotericin in the management of coccidioidal meningitis. Semin. Respir. Infect. 16(4), 263–269 (2001).
   PubMedGoogle Scholar
• Liu KH, Wu CJ, Chou CH et al. Refractory candidal meningitis in an immunocompromised patient cured by caspofungin. J. Clin. Microbiol. 42(12), 5950–5953 (2004).
   PubMed Web of Science ®Google Scholar
• Odio CM, Araya R, Pinto LE et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr. Infect. Dis. J. 23(12), 1093–1097 (2004).
   PubMed Web of Science ®Google Scholar
• Deresinski SC, Stevens DA. Caspofungin. Clin. Infect. Dis. 36, 1445–1457 (2003).
   PubMed Web of Science ®Google Scholar
• Hossain MA, Reyes GH, Long LA, Mukherjee PK, Ghannoum MA. Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans. J. Antimicrob. Chemother. 51, 1427–1429 (2003)
   PubMed Web of Science ®Google Scholar
• Pappas PG, Perfect JR, Cloud GA et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin. Infect. Dis. 33, 690–699 (2004).
   Google Scholar
• Sepkowitz KA. Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clin. Infect. Dis. 4, 98–107 (2002).
   Google Scholar
• Vigouroux S, Morin O, Milpied N, Mahe B, Rapp MJ, Harousseau JL. Cryptococcus neoformans infection in hematologic malignancies. Rev. Med. Interne. 21, 955–960 (2000).
   PubMed Web of Science ®Google Scholar
• Pagano L, Fianchi L, Caramatti C et al. for GIMEMA Infection Program. Cryptococcosis in patients with hematological malignancies. report by GIMEMA-Infection. Haematologica 89, 852–856 (2004).
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Peitsch WK, Reddy BT et al. Cryptococcosis in patients with cancer. Clin. Infect. Dis. 1(32), E145–E150 (2001).
   Google Scholar
• Lortholary O, Charlemagne A, Bastides F et al. A multicentre pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France during 1998–1999. J. Antimicrob. Chemother. 54(2), 456–464 (2004).
   Google Scholar
• Cheng YC, Ling JF, Chang FC et al. Radiological manifestations of cryptococcal infection in central nervous system. J. Chin. Med. Assoc. 66(1), 19–26 (2003).
   PubMedGoogle Scholar
• Gottfredsson M, Perfect JR. Fungal meningitis. Semin. Neurol. 20(3), 307–322 (2000).
   PubMed Web of Science ®Google Scholar
• Saag MS, Graybill RJ, Larsen RA et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin. Infect. Dis. 30(4), 710–718 (2000).
   PubMed Web of Science ®Google Scholar
• Bennett JE, Dismukes WE, Duma RJ et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N. Engl. J. Med. 19(3), 126–131 (1979).
   Google Scholar
• Dismukes WE, Cloud G, Gallis HA et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N. Engl. J. Med. 317(6), 334–341 (1987).
   PubMed Web of Science ®Google Scholar
• White M, Cirrincione C, Blevins A, Armstrong D. Cryptococcal meningitis: outcome in patients with AIDS and patients with neoplastic disease. J. Infect. Dis. 165(5), 960–963 (1992).
   PubMed Web of Science ®Google Scholar
• Polsky B, Depman MR, Gold JW, Galicich JH, Armstrong D. Intraventricular therapy of cryptococcal meningitis via a subcutaneous reservoir. Am. J. Med. 81(1), 24–28 (1986).
   PubMed Web of Science ®Google Scholar
• Denning DW, Armstrong RW, Lewis BH, Stevens DA. Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome. Am. J. Med.91, 267–272 (1991)
   PubMed Web of Science ®Google Scholar
• Girmenia C, Pagano L, Martino B et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J. Clin. Microbiol. 43(4), 1818–1828 (2005).
   PubMed Web of Science ®Google Scholar
• Ogata K, Tanabe Y, Iwakiri K et al. Two cases of disseminated Trichosporon beigelii infection treated with combination antifungal therapy. Cancer 65, 2793–2795 (1990).
   PubMed Web of Science ®Google Scholar
• Amft N, Miadonna A, Viviani MA, Tedeschi A. Disseminated Geotrichum capitatum infection with predominant liver involvement in a patient with non-Hodgkin’s lymphoma. Haematologica 81, 352–355 (1996).
   PubMed Web of Science ®Google Scholar
• Girmenia C, Micozzi A, Venditti M et al. Fluconazole treatment of Blastoschizomyces capitatus meningitis in an allogeneic bone marrow recipient. Eur. J. Clin. Microbiol. Infect. Dis. 10, 752–756 (1991).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Melcher GP, Rinaldi MG et al. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J. Clin. Microbiol. 28, 1616–1622 (1990).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Newman KR, Moody M, Wharton RC, Wade JC. Trichosporonosis in patients with neoplastic disease. Medicine 65, 268–279 (1986).
   PubMed Web of Science ®Google Scholar
• Walsh TJ. Trichosporonosis. Infect. Dis. Clin. North Am. 3, 43–52 (1989).
   PubMedGoogle Scholar
• Hoy J, Hsu KC, Rolston K, Hopfer RL, Luna M, Bodey GP. Trichosporon beigelii infection: a review. Rev. Infect. Dis. 8, 959–967 (1986).
   PubMedGoogle Scholar
• Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin. Microbiol. Infect. 10(Suppl. 1), 48–66 (2004).
   PubMed Web of Science ®Google Scholar
• Anaissie EJ, Hachem R, Karyotakis NC et al. Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichosporonosis. Antimicrob. Agents Chemother. 38, 2541–2544 (1994).
   PubMed Web of Science ®Google Scholar
• Falk R, Wolf DG, Shapiro M, Polacheck I. Multi-drug resistant Trichosporon asahii isolates are susceptible to voriconazole. J. Clin. Microbiol. 41, 911 (2003).
   PubMed Web of Science ®Google Scholar